Avalo Therapeutics Inc (AVTX)vsModerna Inc (MRNA)
AVTX
Avalo Therapeutics Inc
$16.07
-0.68%
HEALTHCARE · Cap: $864.51M
MRNA
Moderna Inc
$143.77
-1.99%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 3776171% more annual revenue ($2.23B vs $59,000). AVTX leads profitability with a 0.0% profit margin vs -141.4%. AVTX earns a higher WallStSmart Score of 25/100 (F).
AVTX
Avoid25
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVTX.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.77
$8.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AVTX
The strongest argument for AVTX centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AVTX
The primary concerns for AVTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AVTX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
AVTX generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
AVTX scores higher overall (25/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avalo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?